Integrated Diagnostics Holdings AI Stock Analysis
Want to see GB:IDHC full AI Analyst Report?
Integrated Diagnostics Holdings (IDHC) AI Stock Analysis
Integrated Diagnostics Holdings
(LSE:IDHC)
Strong financial performance and positive earnings outlook are the primary drivers, complemented by favorable valuation metrics, though technical analysis indicates neutral momentum.
Integrated Diagnostics Holdings (IDHC) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $278.75M
- Dividend Yield
- 5.32%
- Average Volume (3M)
- 555.93K
- Price to Earnings (P/E)
- 9.9
- Beta (1Y)
- 0.59
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 7,137
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Integrated Diagnostics Holdings Business Overview & Revenue Model
Company Description
Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 dist...
How the Company Makes Money
IDHC makes money primarily by performing diagnostic tests and pathology services for patients referred by healthcare providers and billing for those services. Key revenue streams generally include (1) pathology services, where tissue and other specim...
Integrated Diagnostics Holdings Earnings Call Summary
The call was strongly positive overall. Highlights significantly outweighed the lowlights, with 37% revenue growth, record testing volume, expanding margins, 47% net profit growth, improved Nigeria performance, and rapid Saudi expansion. The main challenges were geopolitical uncertainty, constrained Sudan operations, Saudi Arabia remaining below break-even, higher working capital balances, lower net cash, and the decision not to pay an interim dividend.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, management is forecasting revenue of EGP 11 billion, gross profit of 46%, EBITDA margin of 37%, and net profit margin of 20%; margins are expected “to have the same margins until the full year of 2026,” with Q3 and Q4 expected “to be resilient” and “a good second half of 2026 with high margins.” Egypt is expected to add “around 50 more branches in H2,” while Saudi Arabia’s plan is to open nine branches this year, with five opened and four to go, and to reach 50 branches in three years; Nigeria is not expected to open more branches, with the focus on increasing revenue, patient footprint, tests, and profitability from existing branches. Management said a 4% price increase implemented during the second quarter “will continue for the rest of the year,” but also said, “We are not planning to do any price increase for the rest of the year,” and confirmed that “for this quarter, there will be no dividend distribution.”
Integrated Diagnostics Holdings Financial Statement Overview
Summary
Robust income statement with strong revenue rebound and margin expansion, supported by positive cash flow generation and a stable balance sheet with manageable debt.
Income Statement
85Very PositiveBalance Sheet
78PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.17B | 7.86B | 5.72B | 4.12B | 3.61B | 5.22B |
| Gross Profit | 3.97B | 3.35B | 2.18B | 1.52B | 1.46B | 2.80B |
| EBITDA | 2.88B | 2.89B | 2.09B | 1.28B | 1.29B | 2.57B |
| Net Income | 1.51B | 1.26B | 1.08B | 510.30M | 541.11M | 1.41B |
Balance Sheet | ||||||
| Total Assets | 9.31B | 8.60B | 7.13B | 5.77B | 5.30B | 6.24B |
| Cash, Cash Equivalents and Short-Term Investments | 1.96B | 2.13B | 1.75B | 860.51M | 815.92M | 2.35B |
| Total Debt | 1.68B | 1.61B | 1.47B | 1.18B | 1.18B | 858.74M |
| Total Liabilities | 4.59B | 4.46B | 3.63B | 2.67B | 2.85B | 3.44B |
| Stockholders Equity | 3.93B | 3.38B | 2.71B | 2.68B | 2.15B | 2.58B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.38B | 1.34B | 217.73M | -100.11M | 2.01B |
| Operating Cash Flow | 0 | 1.90B | 1.57B | 543.66M | 208.73M | 2.27B |
| Investing Cash Flow | 0 | -552.92M | -446.71M | -243.94M | 990.11M | -1.33B |
| Financing Cash Flow | 0 | -851.06M | -749.00M | -330.46M | -1.62B | -647.15M |
Integrated Diagnostics Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IDHC, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.51, and below the 200-day MA of 0.55, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 58.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IDHC.
Integrated Diagnostics Holdings Peers Comparison
Overall Rating
GB:BVXP89Outperform
GB:IDHC77Outperform
GB:EKF64Neutral
GB:GDR49Neutral
GB:ABDX46Neutral
GB:CNSL43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 89Outperform | GBP 102.93M | 13.59 | 67.81% | 7.61% | -1.10% | 0.32% | |
| 77Outperform | $278.75M | 9.88 | 39.61% | 5.32% | ― | ― | |
| 64Neutral | GBP 102.71M | 41.38 | 3.58% | ― | 2.26% | -57.04% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | GBP 14.45M | -0.82 | -1044.57% | ― | 65.60% | 74.84% | |
| 46Neutral | GBP 21.48M | -15.45 | -34.31% | ― | 30.42% | 43.16% | |
| 43Neutral | GBP 3.45M | -0.55 | -117.38% | ― | -32.11% | -559.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:IDHC | Integrated Diagnostics Holdings | 0.48 | -0.20 | -29.46% | |
| GB:BVXP | Bioventix plc | 1970.00 | -17.97 | -0.90% | |
| GB:EKF | EKF Diagnostics Holdings | 24.00 | -2.20 | -8.40% | |
| GB:GDR | Genedrive plc | 0.90 | 0.11 | 13.92% | |
| GB:CNSL | Omega Diagnostics | 1.45 | -0.80 | -35.56% | |
| GB:ABDX | Abingdon Health PLC | 8.50 | 1.00 | 13.33% |
Integrated Diagnostics Holdings Corporate Events
Insider-Related Share Purchase at Integrated Diagnostics Holdings
PositiveIntegrated Diagnostics Holdings PLC disclosed a significant share purchase by Hena Holdings Ltd, a person closely associated with Chief Executive Officer Dr Hend El Sherbini. The transaction involved the acquisition of 15,580,812 ordinary shares at a...
IDH Delivers Strong H1 Growth as Founders Tighten Control and Cash Is Preserved for Expansion
PositiveIntegrated Diagnostics Holdings reported strong top- and bottom-line growth in the first half of 2026, with revenues rising 37% to EGP 4.9 billion on the back of 20% higher test volumes and a 14% increase in revenue per test. Gross profit climbed 41%...
IDH Schedules Interim 2026 Results and Investor Call
PositiveIntegrated Diagnostics Holdings, a London-listed provider of clinical pathology and radiology services across several Middle Eastern and African markets, plans to publish its unaudited financial results for the second quarter and first half of 2026 o...
Integrated Diagnostics Discloses Mandatory Offer Acceptance by CEO-Linked Investor
NeutralIntegrated Diagnostics Holdings disclosed a transaction involving Hena Holdings Ltd, a person closely associated with chief executive officer Dr Hend El Sherbini. The filing, made under UK Market Abuse Regulation, relates to ordinary shares of $0.25...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 15, 2026
